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We	examined	the	effects	of	fluoxetine,	a	selective	serotonin	re-uptake	inhibitor,	of	sildenafil,	
a	 phosphodiesterase-5	 (PDE5)	 inhibitor,	 and	 of	 combined	 administration	 of	 these	 agents	
on	morphometric	 characteristics	 of	 principal	 cells	 of	 the	murine	 hippocampus.	 Fluoxetine	 
(5	mg/kg),	 sildenafil	 (2	mg/kg),	 or	 a	 combination	 of	 these	 drugs	 in	 the	 above	 doses	were	
administered	 i.p.	daily	 for	2	weeks	 to	male	mice.	Hippocampal	sections	(5	mm	thick)	were	
stained	with	 hematoxylin/eosin.	Both	 drugs	 and	 their	 combination	 evoked	no	 considerable	
changes	 in	 the	dimensions	of	pyramidal	cells	 in	 the	CA1	 and	CA2	 areas	and	 in	 the	dentate	
gyrus	 (DG),	 except	 for	 a	 trend	 toward	 some	 decrease	 of	 this	 parameter	 after	 fluoxetine	
injections	 in	 the	CA1	 area.	Combined	 administration	 of	 fluoxetine	 and	 sildenafil	 provided	
significant	decreases	in	the	density	of	pyramidal	neurons	(their	mean	number	per	10	mm	of	
the	slice)	in	the	CA1	area	and	DG.	Isolated	administration	of	fluoxetine	resulted	in	significant	
but	less	intense	decreases	in	the	density	of	principal	cells	in	the	CA2	area	and	DG.	Possible	
mechanisms	of	the	effects	of	the	mentioned	drugs	are	discussed.	Further	studies	of	interaction	
between	 fluoxetine	 and	 sildenafil	 in	 their	 effects	 on	 morphological	 and	 physiological	
properties	of	cells	in	different	subregions	of	the	hippocampus	are	recommended.
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INTRODUCTION
The	hippocampus	 is	an	 important	brain	structure	 that	
is	 a	 target	 for	 a	 number	 of	 drugs	 [1].	 Hippocampal	
neuronal	systems	are	involved	in	various	physiological	
functions,	 such	 as	 anxiety,	 depression	 [2],	 cognition,	
learning,	and	memory	[3,	4].	It	is	well	known	that	the	
hippocampus	 is	 one	 of	 the	 crucial	 cerebral	 regions	
related	 to	 behavior,	 and	 its	 behavior-controlling	
functions	are	affected	by	many	neuroactive	drugs	 [1,	
2,	4-6].	 In	 the	CNS	of	mammals,	 the	hippocampus	 is	
one	of	the	oldest	brain	regions	from	the	phylogenetic	
aspect.	It	consists	of	two	major	parts,	the	hippocampus	
per se	(Ammon’s	horn,	or	cornu ammonis,	CA)	and	the	
dentate	gyrus	(DG)	[2,	7-9].	The	hippocampus	proper	
includes	three	subregions,	areas	CA1-CA3	[8,	9].	
Fluoxetine,	a	selective	serotonin	re-uptake	inhibitor	
(SSRI)	and	a	known	antidepressant,	is	commonly	used	
in	psychiatry	[2].	It	was	found	that	this	agent	improves	
cell	proliferation	and	neurogenesis	in	the	hippocampus	
[1,	 6].	The	 effects	 of	 fluoxetine	 have	 been	 reported	
with	 respect	 to	 such	 activities	 as	 synaptogenesis	
of	 pyramidal	 cells	 [2],	 plasticity	 of	 astrocytes	 [7],	
expression	 of	 synaptic	 proteins	 [10],	 and	 elevation	
of	 the	 spine	 density	 in	 the	CA1	 area	 and	DG	of	 the	
hippocampus	[8].
On	the	other	hand,	sildenafil,	a	phosphodiesterase-5	
(PDE5)	 inhibitor,	 that	 easily	 penetrates	 the	 CNS,	
increases	the	cGMP	level	[3,	11].	Sildenafil	intensifies	
neurogenesis	 and	 promotes	 functional	 recovery	
after	 ischemia	 [12,	 13],	 induces	 angiogenesis	 [12],	
and	 increases	 the	 number	 of	 varicosities	 in	 the	CA3 
region	of	the	hippocampus	[4].	In	addition,	sildenafil	
is	 useful	 for	 reversing	 sexual	 dysfunction	 resulting	
from	 SSRI	 actions,	 including	 fluoxetine	 [14,	 15].	
The	 efficacy	 of	 combined	 treatment	 by	 fluoxetine	
and	 sildenafil	 in	 anxiety,	 depression,	 and	 fertility	
disorders	has	been	reported	[11,	14-16];	recent	studies	
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indicated	that	nitric	oxide	synthase	(NOS)	activity	 in	
the	hippocampus	mediates	 the	effect	of	 fluoxetine	 in	
mice	[17].	
Considering	 the	 beneficial	 functional	 effects	 of	
fluoxetine	and	sildenafil	mentioned	above,	our	study	
was	 undertaken	 to	 examine	 the	 effects	 of	 systemic	
administration	of	 fluoxetine	 and	 sildenafil	 and	 their	
co-administration	 on	 morphological	 characteristics	
of	 principal	 neuronal	 components	 of	 the	 murine	
hippocampus.	
METHODS
Animals. Experimental	N-MARI	male	mice	(30	to	35	g;	 
n	 =	 20)	 were	 obtained	 from	 the	 breeding	 colony	 of	
the	 Iran	 Pasteur	 Institute	 (Tehran)	 and	 randomly	
distributed	 into	 four	 groups	 (five	 animals	 in	 each).	
Mice	were	housed	at	a	constant	temperature	of	20	±	2°C	 
with	a	12:12	h	light/dark	cycle	(lights	on	at	7:00	a.m)	
with	free	access	to	food	and	water	ad libitum.	
Drug Treatment. One	week	after	acclimatization,	
experimental	mice	were	 i.p.	 treated	with	 fluoxetine	
(5	mg/kg;	Tocris,	Great	Britain),	sildenafil	 (2	mg/kg;	
Vorin,	 India),	or	a	combination	of	 these	drugs	 in	 the	
above	doses	once	a	day	 for	15	consecutive	days	 [2].	
Control	 animals	 received	 a	 vehicle.	The	 drugs	were	
freshly	 prepared	 each	 day	 in	 physiological	 saline.	
The	doses	of	drugs	were	calculated	according	 to	 the	
baseline	weight	of	each	animal.	
Experimental  Procedure.  The	 mice	 were	
anesthetized	 by	 a	 mixture	 of	 xylasine/ketamine	
3	 h	 after	 the	 last	 drug	 or	 vehicle	 injection	 [2],	
transcardially	 perfused	 with	 0.9%	 saline	 followed	
by	 formalin,	 and	 decapitated.	 The	 brains	 were	
immediately	 removed,	 post-fixed	 in	 fresh	 Bouin	
solution	for	at	least	7	days,	and	embedded	in	paraffin.	
Using	 a	 rotatory	microtome,	 serial	 coronal	 sections	
of	 the	brain	 (5	µm	thick)	were	cut	 through	 the	entire	
hippocampus.	A	stereotaxic	brain	atlas	[9]	was	used	for	
reference	during	sectioning	procedures.	After	standard	
dehydration,	 fixation,	 embedding	 into	 paraffin,	 and	
deparaffinization	 procedures,	 the	 sections	 were	
stained	using	a	standard	hematoxylin/eosin	technique.	
Slices	were	examined	at	a	400×	magnification	under	
a	BA	400	microscope	(Motic,	Spain)	equipped	with	a	
camera	output	to	a	computer	monitor.	The	images	were	
stored	 using	 the	 respective	 software	 and	 assembled	
using	 brightness	 at	 a	 level	 of	 +50.	 In	 the	 coronal	
sections	of	the	hippocampus,	the	number	(density)	of	 
principal	neurons,	 their	 dimension,	 and	 thickness	of	
the	pyramidal	 layer	were	measured	 in	 the	CA1,	CA2,	
and	CA3	regions	and	also	in	the	DG.	The	alteration	of	
the	neurons	was	estimated	with	 the	optical	dissector	
following	a	fractionator	principle	[7].	
Statistical Analyses. All	numerical	data	are	shown	
as	 means	 ±	 s.e.m.	 The	 significance	 of	 intergroup	
differences	 was	 calculated	 by	 one-way	 ANOVA	
followed	 by	 the	 post-hoc	 Tukey	 test	 for	 multiple	
comparisons.	The	statistical	significance	was	defined	
at	P	<	0.05.	
RESULTS 
Figure	1	illustrates	the	effects	of	fluoxetine,	sildenafil,	
or	a	combination	of	these	agents	on	the	dimension	of	
principal	cells	in	the	CA1,	CA2,	and	DG	subfields	of	the	
hippocampus.	As	 can	 be	 seen,	 isolated	 introductions	
of	fluoxetine	led	to	some	trend	to	toward	a	decrease	in	
this	parameter	in	the	CA1	area	(Fig.	1A).	Nonetheless,	
one-way	ANOVA	showed	that	differences	between	the	
mean	 dimensions	 of	 principal	 cells	 in	 the	mentioned	
hippocampal	 regions	 related	 to	 both	 isolated	 and	
combined	 treatment	 with	 the	 above	 agents	 did	 not	
reach	the	level	of	significance.
Figure	 2	 illustrates	 the	 effects	 of	 drug	 treatment	
on	 the	 density	 of	 principal	 cells	 in	 three	 regions	 of	
the	 hippocampus	 under	 study.	 One-way	 ANOVA	
revealed	 significant	 differences	 between	 the	 effects	
in	 the	 groups.	 The	 Tukey-Kramer	 test	 showed	 that	
a	 combination	 of	 fluoxetine	 and	 sildenafil	 provided	
significant	decreases	 in	 the	density	of	principal	cells	
(their	mean	number	per	10	mm	of	the	slice)	in	the	CA1 
area	and	DG	(P	<	0.01,	A,	C).	It	should	be	mentioned	
that	 isolated	 introductions	 of	 fluoxetine	 induced	
considerable	decreases	 in	 the	cell	density	 in	 the	CA2 
area	 and	 DG	 (P	 <	 0.05	 and	P	 <	 0.01,	 respectively,	
B,	C).	At	 the	same	 time,	 isolated	action	of	 sildenafil	
did	 not	 evoke	 significant	 changes	 in	 the	 density	 of	
principal	 cells	 in	 all	 the	 regions	 examined	 (only	
mild	 insignificant	 trends	 toward	 decrease	 could	 be	
noticed;	A-C).	Upon	the	combined	action	of	the	above-
mentioned	agents,	the	cell	density	in	the	CA2	area	was	
practically	similar	to	that	in	the	control	(B).
In	Fig.	 3,	 photomicrographs	of	 slices	 of	 the	CA1,	
CA2,	 and	 DG	 regions	 of	 the	 hippocampus	 of	 mice	
treated	 for	2	weeks	with	 fluoxetine,	 sildenafil,	 and	a	
combination	of	fluoxetine	and	sildenafil	or	vehicle	are	
shown.
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F i g. 1.	Mean	dimensions	(diameters,	mm)	of	principal	(pyramidal)	
cells	 in	 the	CA1	 area,	CA2	 area,	 and	 dentate	 gyrus	 (DG)	 of	 the	
hippocampus	(A-C,	respectively)	of	mice	treated	for	2	weeks	with	
fluoxetine	(Fluox),	sildenafil	(Sild),	and	their	combination.	Contr.	is	
the	control	group.	Means	±	s.e.m.	are	shown.
Р и с. 1.	Середні	розміри	(діаметр,	мкм)	головних	(пірамідних)	
клітин	у	зонах	СА1	та	СА2	і	в	зубчастій	звивині	гіпокампа	(А–C 
відповідно)	мишей,	яким	уводили	флуоксетин,	силденафіл	або	
їх	комбінацію.
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F i g. 2.	 Mean	 densities	 (numbers	 per	 10	 mm	 of	 the	 slice)	 of	
pyramidal	 cells	 in	 the	 CA1	 area,	 CA2	 area,	 and	 dentate	 gyrus	
of	 the	 hippocampus	 (A-C,	 respectively)	 of	 mice	 treated	 with	
fluoxetine	 (Fluox),	 sildenafil	 (Sild),	 and	 their	combination.	**P < 
0.01	 compared	 to	 the	 control	 group,	 ##P	 <	0.01	 compared	 to	 the	
Fluox	 group,	 and	 ×	P	 <	 0.05	 compared	 to	 the	 Sild	 group.	Other	
designations	are	similar	to	those	in	Fig.	1.
Р и с. 2.	 Середні	щільності	 (кількість	 на	 10	 мкм	 зрізу)	 піра-
мідних	 нейронів	 у	 зонах	 СА1	 та	 СА2	 і	 в	 зубчастій	 звивині	
гіпокампа	(А–С	відповідно)	мишей,	яким	уводили	флуоксетин,	
силденафіл	або	їх	комбінацію.
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F i g. 3.	 Photomicrographs	 of	 hematoxylin/	
eosin-stained	 slices	of	 the	hippocampus.	A)	At	
a	low	magnification,	B)	at	a	high	magnification.	
Regions	 of	 the	 hippocampus	 are	 shown	 at	 the	
left;	designations	of	the	groups	similar	to	those	
in	Figs.	1	and	2	are	shown	above.	
Р и с. 3.	 Мікрофотографії	 зрізів	 гіпокампа	
(забарвлення	гема	токсиліном/еозином).
DISCUSSION
In	 this	study,	we	evaluated	counts	and	dimensions	of	
principal	 neurons	 in	 the	CA1,	CA2,	 and	 DG	 regions	
of	the	hippocampus	after	two	weeks	of	treatment	with	
fluoxetine,	sildenafil,	or	a	combination	of	these	agents.	
Fluoxetine	 inhibits	 SERT	 activity	 and	 increases	
extracellular	 levels	 of	 serotonin	 [2].	 Serotonin	 is	
known	to	regulate	neurogenesis	and	cell	proliferation	
and	 to	 facilitate	 the	 growth	 of	 neurons	 [1,	 2,	 6,	 7].	
An	 increasing	serotonin	 level	 resulting	 from	chronic	
administration	of	 fluoxetine	considerably	affects	 the	
hippocampus	 [1,	 6,	 7].	 Possible	mechanisms	 of	 the	
effect	 of	 fluoxetine	 (an	 SSRI	 antidepressant)	might	
A
B
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be	 attributed	 to	 changes	 in	 the	 level	 of	 neurotropic	
factors,	neural	growth,	and	synaptic	plasticity	 [7].	 In	
addition,	previous	studies	demonstrated	that	treatment	
with	 fluoxetine	 promotes	 cell	 proliferation	 in	 the	
case	 of	 stress	 [1,	 7]	 and	 increases	 neurogenesis	 and	
cell	proliferation	 in	 the	hippocampus	 [1,	6].	Chronic	
administration	of	fluoxetine	was	reported	to	influence	
expression	 of	 several	 synaptic	 proteins	 [10],	 to	
intensify	the	process	of	synaptogenesis,	and	to	restore	
the	synaptic	density	in	the	hippocampus	[2].	
Sildenafil,	 which	 successfully	 crosses	 the	 blood-
brain	barrier	[18],	inhibits	PDE5	in	the	CNS	[4].	The	
activity	 of	 guanylyl	 cyclase	 (GC),	 the	 enzyme	 that	
mediates	production	of	cGMP,	is	known	to	be	initiated	
by	 activation	 of	 NOS	 and	 increase	 in	 nitric	 oxide	
(NO)	production	[18].	A	few	experiments	showed	that	
sildenafil,	 as	 a	 selective	 PDE5	 inhibitor,	 increases	
cGMP	 accumulation	 in	 the	 hippocampus	 [4].	 The	 
NO/cGMP	 pathway	 mediates	 protein	 modifications	
[19].	 In vitro	 studies	 demonstrated	 that	 high	 levels	
of	 cGMP	modulate	differentiation	of	 stem	cells	 into	
neurons	 [5].	 Sildenafil,	 at	 the	 same	 time,	 exerts	 a	
protective	effect	against	neurodegeneration,	increases	
cell	 survival	 [5],	 induces	an	 increase	 in	 the	contents	
of	 a	 few	 proteins,	 and	 mediates	 a	 long-lasting	
neuroprotective	 effect	 of	 the	 hippocampus	 [12].	
This	 PDE5	 inhibitor	 enhances	 the	 cGMP	 levels	 in	
varicosities	 in	 the	hippocampus	 [4].	Relatively	mild	
effects	of	sildenafil	 found	in	our	study	are,	probably,	
related	 to	 the	duration	of	 treatment,	a	 relatively	 low	
dose	of	sildenafil,	and	peculiarities	of	the	histological	
method	used.	
The	 hippocampus	 is	 rich	with	NOS	 and	GC	 [20].	
The	NO–cGMP	pathway	has	an	important	modulatory	
effect	on	 the	 serotonergic	 system	[17,	21].	Systemic	
administration	of	a	NO	inhibitor	 increases	 the	efflux	
of	serotonin	in	the	hippocampus	[21].	In	serotonergic	
neurons,	 the	 serotonin	 re-uptake	 transporter	 (SERT)	
is	 co-localized	with	 NOS	 [22].	 Interaction	 between	
NOS	and	SERT	negatively	modulates	SERT	activity	
and	increases	nNOS	activity	and	cGMP	accumulation,	
thus	enhancing	serotonin	 re-uptake	 [20-22].	 It	 seems	
possible	 that	 interaction	 between	 fluoxetine	 and	
sildenafil	can	provide	the	above	effects.	
Our	 results	 show	 that,	 in	 the	 case	 of	 relatively	
long	 (2	weeks)	 systemic	 administration,	 fluoxetine,	
sildenafil,	and	 their	combination	exert	certain	effects	
on	 morphometric	 characteristics	 of	 principal	 cells	
in	 the	 murine	 hippocampus.	 With	 respect	 to	 the	
dimensions	 of	 pyramidal	 cells,	 the	 effects	 of	 these	
drugs,	 applied	 in	 any	 mode	 in	 the	 doses	 used,	 did	
not	 reach	 the	 level	of	 significance	 (a	 trend	 toward	a	
decrease	 in	 the	mentioned	parameter	 in	 the	CA1	area	
under	 the	 action	 on	 fluoxetine	 deserves,	 however,	
certain	attention).	At	 the	same	 time,	 there	were	clear	
decreases	 in	 the	number	 (density)	of	pyramidal	cells	
in	the	CA1	area	and	DG	under	conditions	of	combined	
treatment	 with	 fluoxetine	 and	 sildenafil.	 Thus,	 it	
seems	that	positive	functional	effects	of	a	combination	
of	 these	 drugs	 [11,	 14-16]	 can	 be	 accompanied	 by	
structural	 shifts	 in	 the	 hippocampus,	 which	 should	
be	 interpreted	 as	 negative	 from	 a	 certain	 aspect.	At	
the	same	time,	it	should	be	mentioned	that	fluoxetine,	
when	applied	in	an	isolated	mode,	also	led	to	decreases	
in	 the	number	of	principal	cells,	but	not	 in	 the	same	
hippocampal	zones	(this	effect	was	obvious	in	the	CA2 
area	and	DG;	Fig.	2B,	C).	
Thus,	 our	 study	 showed	 that	 chronic	 treatment	
with	fluoxetine	influences	the	regular	arrangement	of	
pyramidal	neurons	in	some	parts	of	the	hippocampus.	
The	 effect	 of	 co-administration	 of	 fluoxetine	 and	
sildenafil	with	respect	to	the	number	(density)	of	these	
principal	cells	differs	 from	that	of	 fluoxetine	applied	
in	 an	 isolated	 manner.	 The	 effects	 of	 fluoxetine	
and	 sildenafil	 on	 morphometric	 characteristics	 of	
pyramidal	 hippocampal	 neurons	 are	 not	 additive.	
These	 facts	 show	 that	 further	 research	of	 the	effects	
of	systemic	administration	of	these	drugs	in	different	
subfields	 of	 hippocampus	 using	 morphological	
(morphometric),	pharmacological,	 and	physiological	
approaches	is	needed.	
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Р	е	з	ю	м	е
Ми	 досліджували	 вплив	флуоксетину	 (селективного	 інгі-
бітора	 зворотного	 захвату	серотоніну),	 силденафілу	 (інгі-
бітора	фосфодіестерази-5,	PDE5)	та	 їх	сукупного	введення	
на	морфометричні	характеристики	основних	 (пірамідних)	
клітин	гіпокампа	мишей.	Флуоксетин	(5	мг/кг),	силденафіл	 
(2	мг/кг)	або	комбінація	цих	агентів	у	зазначених	дозах	уво-
дилися	самцям	мишей	внутрішньоочеревинно	щоденно	про-
тягом	двох	тижнів.	Зрізи	гіпокампа	завтовшки	5	мкм	забарв-
лювали	гематоксиліном	та	еозином.	Обидві	речовини	та	 їх	
комбінація	не	викликали	значних	змін	розмірів	пірамідний	
нейронів	у	зонах	CA1,	CA2	та	зубчастої	звивини	(ЗЗ),	пев-
на	тенденція	до	зменшення	зазначеного	параметра	спосте-
рігалася	після	ін’єкцій	флуоксетину	в	зоні	CA1.	Сукупна	дія	
флуоксетину	та	силденафілу	призводила	до	істотного	змен-
шення	щільності	 пірамідних	 нейронів	 (їх	 середньої	 кіль-
кості	 з	розрахунку	на	10	мкм	зрізу)	у	 зоні	CA1	 та	ЗЗ.	Об-
говорюються	можливі	механізми	ефектів	згаданих	агентів.	
Доцільними	є	подальші	дослідження	особливостей	взаємо-
дії	флуоксетину	та	силденафілу	на	морфологічні	та	фізіоло-
гічні	характеристики	клітин	у	різних	підрозділах	гіпокампа.
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